[{"id":"d4abf529-67b2-46e8-a739-11f0991f275a","acronym":"RTB","url":"https://clinicaltrials.gov/study/NCT03284268","created_at":"2021-01-18T16:13:30.310Z","updated_at":"2024-07-02T16:35:08.341Z","phase":"","brief_title":"Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma","source_id_and_acronym":"NCT03284268 - RTB","lead_sponsor":"Fundació Sant Joan de Déu","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-22"},{"id":"b8938d92-36d0-423c-9eba-e8257f8d60ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03799744","created_at":"2021-01-18T18:46:56.979Z","updated_at":"2025-02-25T15:08:14.577Z","phase":"Phase 1","brief_title":"Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT03799744","lead_sponsor":"Institut Català d'Oncologia","biomarkers":" IL6 • IL10","pipe":"","alterations":" ","tags":["IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2022-03-28"}]